66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
May 2019 in “Journal of clinical oncology” Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
October 2025 in “Frontiers in Endocrinology” Methimazole for hyperthyroidism has known and new side effects needing more study for safety.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
12 citations
,
June 2016 in “Clinical and Molecular Hepatology” Mycophenolate mofetil can effectively treat autoimmune hepatitis when standard drugs fail.
24 citations
,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
January 2026 in “Vestnik dermatologii i venerologii” Tacrolimus ointment is effective for various skin conditions but needs more research for long-term effects.
Baricitinib shows promise for treating alopecia areata with mild side effects.
10 citations
,
August 2016 in “Dermatology Online Journal” Nilotinib can cause skin issues like red bumps and hair loss.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
February 2017 in “Cancer Research” Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
74 citations
,
February 2011 in “Headache The Journal of Head and Face Pain” Sumatriptan injections, high-flow oxygen, and verapamil effectively treat cluster headaches.
9 citations
,
November 2017 in “International Journal of Nanomedicine” Tiny particles called anionic squarticles can effectively remove a common antidepressant from the body after an overdose.
November 2023 in “Pakistan Journal of Health Sciences” Clobetasol propionate 0.05% is more effective for hair re-growth in alopecia areata than tacrolimus 0.1%.
January 2001 in “대한피부과학회지” Minipulse therapy with betamethasone effectively promotes hair regrowth in alopecia areata with fewer side effects.
2 citations
,
November 1978 in “JAMA” Valproic acid is an effective seizure medication with some temporary side effects.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
21 citations
,
April 2011 in “Epilepsia” The drug combination significantly reduced epileptic drop attacks in patients.
16 citations
,
December 2001 in “The Journal of Dermatology” A woman recovered from hair loss and skin eruptions after stopping a tuberculosis drug and using steroids.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
22 citations
,
May 2017 in “Journal of dermatological treatment” BD 1/4 dilution is the best for treating localized alopecia areata in adults.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
January 2024 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib may be safe and effective for treating certain skin conditions in children.